Skip to main content
Premium Trial:

Request an Annual Quote

Michael Brown, Anthony Murabito, Daniel Geffken, John Marshall Green, Babru Samal


Michael Brown has been reassigned from staff counsel to intellectual property counsel and technology transfer manager at The Institute for Genomic Research, Rockville, Md. He will be responsible for expanding the scope of TIGR’s technology transfer activities.

Prior to TIGR, Brown was a manager of grants and contracts in the office of research and development at the University of Maryland, Baltimore, and the administrator for the Institute of Health Policy, Outcomes and Human Values at George Washington University in Washington.

Transkaryotic Therapies of Cambridge, Mass., has named Anthony Murabito vice president, management information systems. In this role, Murabito will be responsible for TKT’s information technology and telecommunications systems.

Murabito joins TKT from SmithKline Beecham where he most recently held the position of group director, information management research and development.

TKT also promoted Daniel Geffken to senior vice president, finance, and chief financial officer.

InforMax, Rockville, Md., has named John Marshall Green as senior vice president and chief financial officer. He replaces Joseph Lehnen, who has resigned.

Green was previously executive vice president, operations, North America, for HMSHost Corporation (formerly Host Marriott Services). He also held senior management positions with Marriott International and PepsiCo.

Babru Samal, previously director of bioinformatics and molecular biology at Imgenex, has joined NeuralStem Biopharmaceuticals as principal scientist, gene discovery.

Samal and four other new hires bring College Park, Md.-based NeuralStem’s total number of employees to 34, up from 14 a year ago.

Filed under

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.